The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

CI Insights From Zepbound to AD109, pharma innovation is reshaping Obstructive Sleep Apnea. Discover key players, C ...

Insulin efsitora alfa (investigational once-weekly basal insulin): In another ADA-sponsored symposium, Lilly will share results from the QWINT-1, QWINT-3 and QWINT-4 Phase 3 trials, which evaluated ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Ever since blockbuster weight-loss drugs like Wegovy and Zepbound went mainstream, calls to local poison control centers ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy.